- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Fixed-Duration Options for CLL
Panelists discuss how fixed-duration options like venetoclax plus obinutuzumab show promise in treating chronic lymphocytic leukemia (CLL) by offering defined treatment periods rather than indefinite therapy.
Content above is prompted by the following:
- A key distinction between preferred upfront therapies for CLL—venetoclax-based regimens and Bruton tyrosine kinase (BTKi)–based regimens—is that venetoclax offers a fixed-duration option, while BTKi therapy is typically continuous. However, studies presented at the 2024 American Society of Hematology annual meeting explored the efficacy and safety of fixed-duration BTKi therapy in the first-line setting. How might adopting fixed-duration BTKi therapy influence treatment choices in the relapsed/refractory CLL setting?
MRD Status Prior to Allo-HSCT Shows Strong Prognostic Value in AML, MDS
January 6th 2025A study demonstrated that pre-transplant measurable residual disease (MRD) status is a strong prognostic factor for overall survival, disease-free survival, and relapse risk in patients with AML and MDS undergoing allogeneic stem cell transplantation.
Read More
Male Patients With Eosinophilic Esophagitis Face Higher Complication Rates
January 6th 2025Compared with female patients, male patients with eosinophilic esophagitis have higher rates of complications, including esophageal obstruction, food impaction, and rupture, highlighting potential gender differences in disease severity.
Read More
